DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Market and Competitive Landscape – 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights into Dry Eye pipeline, epidemiology, market valuations, drug sa…
Month: September 2021
Ophthalmology Drug Pipeline Database 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Pipeline Database – 2021” report has been added to ResearchAndMarkets.com’s offering. Ophthalmology Pipeline Highlights Database – 2021, provides the most up-to-date information on key pipeline products in th…
Patient enrollment finalized for Stuart’s phase 2 dry eye disease trial
Stuart Therapeutics has completed patient enrollment in a phase 2 clinical trial of ST-100 for the treatment of dry eye disease.The drug candidate is based on PolyCol, a synthesized polypeptide tissue reparative platform.The multicenter, randomized, do…
EXALT Model B Single-Use Bronchoscope: Interview with Dave Pierce, Boston Scientific
Boston Scientific recently announced FDA clearance of the EXALT Model B single-use bronchoscope, intended for bedside procedures in intensive care units or in the operating room. As a single-use device that boasts high quality imaging and suction capabilities, the bronchoscope is ready to go out of the packaging, which means it mitigates the risk of […]
EyeGate completes enrollment in ocular surface inflammation study
EyeGate Pharmaceuticals has completed enrollment in a phase 2 proof-of-concept study investigating PP-001 in patients with ocular surface inflammation, according to a press release.Twenty-one patients in Austria were enrolled in the randomized, double-…
Q&A: Academia lacks structures to support health care professionals in times of grief
Additional support and flexibility in academia following a loss can foster recovery and may help reduce burnout among health care professionals, according to an opinion piece published in JAMA.Krista Harrison, PhD, a faculty member in the division of g…
Retinopathy Of Prematurity (Ophthalmology) Drugs Pipeline Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinopathy Of Prematurity (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipelin…
jCyte Announces Appointment of Victor Chao as Vice President of CMC Operations
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the Company’s leadership team with the appointmen…
Infectious Endophthalmitis (Ophthalmology) Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Infectious Endophthalmitis (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for I…
Persistent Corneal Epithelial Defects Drugs Pipeline Landscape Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Persistent Corneal Epithelial Defects (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under develo…
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Exec…
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Raj Maturi, M…
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Warby Parker Announces Investor Day
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc., a founder-led direct-to-consumer lifestyle brand, today announced that it will hold an Investor Day Monday, September 13th. The pre-recorded event will be available beginning at 11 a.m. ET/8:00 a.m. PT. Reg…
Specialist details features of successful presbyopia drop
Therapeutic drops are an emerging treatment for patients with presbyopia, with at least eight companies developing products.Jennifer M. Loh, MD, said at the Women in Ophthalmology Summer Symposium that the goal for any presbyopia treatment is to increa…
TearClear files investigational new drug application for glaucoma drop
TearClear has filed an investigational new drug application for its glaucoma drop candidate.If the application is approved, the company plans to initiate a clinical trial to evaluate TC-002 latanoprost ophthalmic solution 0.005%. The solution will be p…
Nimble Therapeutics Appoints Cyrus Arman, PhD, MBA as Chief Business Officer
MADISON, Wis.–(BUSINESS WIRE)–Nimble Therapeutics, an industry-leading peptide therapeutic discovery and optimization company, today announced the appointment of Dr. Cyrus Arman as Chief Business Officer. Cyrus will be responsible for structuring str…
First patient enrolled in phase 4 trial of Tepezza for chronic thyroid eye disease
The first patient has been enrolled in a phase 4 clinical trial to evaluate the safety and efficacy of Tepezza in patients with chronic thyroid eye disease, according to a press release from Horizon Therapeutics.“It is common for patients who are in th…
U.S.Vision Announces New Partnership with Eyewear Brand, MITA
BLACKWOOD, N.J.–(BUSINESS WIRE)–U.S.Vision has partnered with Miami-based MITA Eyewear to become the exclusive distributor of the brand’s optical frame assortment.
Exegenesis Bio Opens Philadelphia and Boston Offices and Announces Expansion Plans
PHILADELPHIA–(BUSINESS WIRE)–Global gene therapy company announces plans to create up to 50 new jobs in Philadelphia and Boston. Launches next phase in global expansion.